Cargando…
Biomarkers of response to ibrutinib plus nivolumab in relapsed diffuse large B-cell lymphoma, follicular lymphoma, or Richter's transformation
We analyzed potential biomarkers of response to ibrutinib plus nivolumab in biopsies from patients with diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and Richter's transformation (RT) from the LYM1002 phase I/IIa study, using programmed death ligand 1 (PD-L1) immunohistochemi...
Autores principales: | Hodkinson, Brendan P., Schaffer, Michael, Brody, Joshua D., Jurczak, Wojciech, Carpio, Cecilia, Ben-Yehuda, Dina, Avivi, Irit, Forslund, Ann, Özcan, Muhit, Alvarez, John, Ceulemans, Rob, Fourneau, Nele, Younes, Anas, Balasubramanian, Sriram |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Neoplasia Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7723809/ https://www.ncbi.nlm.nih.gov/pubmed/33395752 http://dx.doi.org/10.1016/j.tranon.2020.100977 |
Ejemplares similares
-
Circulating tumor DNA for comprehensive noninvasive monitoring of lymphoma treated with ibrutinib plus nivolumab
por: Bruscaggin, Alessio, et al.
Publicado: (2021) -
Ibrutinib has some activity in Richter's syndrome
por: Giri, S, et al.
Publicado: (2015) -
A phase 2 study of nivolumab combined with ibrutinib in patients with diffuse large B-cell Richter transformation of CLL
por: Jain, Nitin, et al.
Publicado: (2022) -
Identification of a genetic signature enriching for response to ibrutinib in relapsed/refractory follicular lymphoma in the DAWN phase 2 trial
por: Balasubramanian, Sriram, et al.
Publicado: (2021) -
Rare Richter Transformation of Chronic Lymphocytic Lymphoma to Hodgkin Lymphoma
por: Buckley, Tinera, et al.
Publicado: (2021)